作者: Karen Bieback , Viet Anh-Thu Ha , Andrea Hecker , Melanie Grassl , Sven Kinzebach
DOI: 10.1089/TEN.TEA.2009.0727
关键词:
摘要: Mesenchymal stromal cells (MSCs) are promising candidates for innovative cell therapeutic applications. For clinical scale manufacturing regulatory agencies recommend to replace fetal bovine serum (FBS) commonly used in MSC expansion media as soon equivalent alternative supplements available. We already demonstrated that pooled blood group AB human (HS) and thrombin-activated platelet releasate plasma (tPRP) support the of multipotent adipose tissue-derived MSCs (ASCs). Slight differences size, growth pattern adhesion prompted us investigate level equivalence by compiling transcriptional profiles ASCs cultivated these supplements. A whole genome gene expression analysis was performed data verified polymerase chain reaction protein analyses. Microarray-based screening 34,039 genes revealed 102 differentially expressed cultured with FBS compared HS or tPRP significantly higher cultures found 90 (fold change ≥2). Only 12 showed a lower ≤0.5). Differences between were hardly evident. Supporting previous observations reduced alternatives we detected number extracellular matrix-associated molecules at levels Confirmative assays analyzing transcript selected supported results. Likewise mesodermal differentiation-associated grown FBS. Quantifying adipogenic osteogenic differentiation lacked demonstrate clear correlation supplement due donor-specific variances. Our results emphasize necessity comparability studies they indicate induces culture adaptation exceeding ex vivo thus may contribute potential.